{"id":89111,"date":"2026-05-12T22:25:24","date_gmt":"2026-05-13T04:25:24","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=89111"},"modified":"2026-05-13T16:45:19","modified_gmt":"2026-05-13T22:45:19","slug":"aetna-denies-wegovy-appeal-strategy","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/aetna-denies-wegovy-appeal-strategy\/","title":{"rendered":"What to Do When Aetna Denies Wegovy: Appeal Strategy"},"content":{"rendered":"

Introduction<\/h2>\n

Aetna denies Wegovy\u00ae more often than people expect. The most common reasons fall into a short list: missing prior authorization, no documented 6-month lifestyle program, BMI below the plan threshold, formulary exclusion through the employer, or a step-therapy requirement for phentermine or Contrave first. Each of these has a specific counter.<\/p>\n

The good news is that internal appeal data published by CMS in 2023 showed roughly 41 percent of commercial denials get overturned when patients file a formal written appeal with new clinical documentation. With Wegovy specifically, the use has gotten stronger after the SELECT trial (Lincoff et al. 2023, NEJM) showed a 20 percent reduction in major cardiovascular events. That cardiovascular indication, approved by FDA in March 2024, changed Aetna’s coverage logic for many plans.<\/p>\n

This guide walks through the exact appeal path: what to include, what to leave out, and which clinical citations carry weight with Aetna’s medical reviewers.<\/p>\n

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n

Why Does Aetna Deny Wegovy?<\/h2>\n

Aetna issues five denial codes that cover about 85 percent of Wegovy rejections.<\/strong> The codes are: PA-NOT-MET (prior authorization criteria missing), NF (non-formulary on this plan), STEP-REQ (step therapy required), BMI-NOT-MET (BMI below 30 without comorbidities or 27 with comorbidities), and EMP-EXCL (employer carved out weight-loss drugs).<\/p>\n

Quick Answer: About 41 percent of commercial insurance denials are overturned on appeal when new documentation is submitted (CMS 2023 data)<\/p>\n

Pull your Explanation of Benefits letter and find the denial reason code. The wording is on page 1 or 2, usually near a phrase that reads “Reason for denial.” The strategy changes completely depending on which code you got. An employer carve-out cannot be appealed through Aetna because the employer wrote the benefit design. Everything else can.<\/p>\n

If the EOB lists “medical necessity not established,” that’s the easiest category to overturn because you can submit chart notes, BMI documentation, and prior weight-loss attempts.<\/p>\n

What Is Aetna’s 2026 Prior Authorization Criteria for Wegovy?<\/h2>\n

Aetna’s 2026 commercial PA criteria for Wegovy require four things: a BMI of 30 or higher, or BMI 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea, plus documentation of a structured weight management program lasting at least 6 months, plus a prescriber attestation that lifestyle changes alone have failed, plus age 18 or older.<\/strong><\/p>\n

For the cardiovascular indication added in 2024, the criteria are different. You need established cardiovascular disease (prior MI, stroke, or symptomatic PAD) and BMI 27 or higher. The lifestyle program requirement is waived under the CV indication on most Aetna plans.<\/p>\n

If your prescriber didn’t submit the chart notes proving the 6-month lifestyle program, the PA will be denied automatically. That’s the most common single fix.<\/p>\n

How Do I File a Level-1 Internal Appeal with Aetna?<\/h2>\n

You have 180 days from the date on the denial letter to file a level-1 internal appeal.<\/strong> The submission goes to the Aetna address listed on your EOB, usually a Pharmacy Appeals PO Box in Phoenix, Arizona or Hartford, Connecticut depending on your plan.<\/p>\n

The appeal packet should include: a written appeal letter signed by you, a separate Letter of Medical Necessity signed by your prescriber, copies of relevant chart notes covering the past 12 months, BMI and weight history, documentation of the 6-month weight management program (commercial program receipts, dietitian visits, or primary care weight counseling notes count), and prior medication trials with dates and outcomes.<\/p>\n

Aetna has 30 days to respond on a standard appeal and 72 hours on an expedited appeal. Expedited appeals require your prescriber to attest that a delay would seriously jeopardize your health. For Wegovy, an expedited claim is reasonable if you have established CVD or uncontrolled type 2 diabetes.<\/p>\n

What Should the Letter of Medical Necessity Say?<\/h2>\n

The LMN is the single most important document in the packet.<\/strong> It needs to be on your prescriber’s letterhead, signed and dated, and it should hit five points directly.<\/p>\n

First, your current BMI and weight, plus the BMI trend over the prior 24 months. Second, every comorbidity that meets Aetna’s criteria, with ICD-10 codes. Third, a list of prior weight-loss interventions with start dates, end dates, and reasons for discontinuation, including any GLP-1 trials, phentermine, Contrave, Qsymia, or commercial programs. Fourth, a clinical rationale citing the STEP 1 trial (Wilding et al. 2021, NEJM) showing 14.9 percent weight loss at 68 weeks, and SELECT (Lincoff et al. 2023, NEJM) showing 20 percent MACE reduction. Fifth, a statement that lifestyle modifications alone have not produced sustained clinical response.<\/p>\n

Keep the letter under two pages. Aetna reviewers spend an average of 6 minutes per appeal file. A wall of text gets skimmed.<\/p>\n

What Clinical Evidence Carries the Most Weight?<\/h2>\n

Aetna’s pharmacy and therapeutics committee references specific trials when updating coverage policy.<\/strong> Citing those trials by name puts your appeal in their internal language.<\/p>\n

The STEP program (Wilding et al. 2021 NEJM, Davies et al. 2021 Lancet, Wadden et al. 2021 JAMA) covers Wegovy in obesity, with and without diabetes, and with behavioral therapy. STEP-HFpEF (Kosiborod et al. 2023, NEJM) shows benefit in heart failure with preserved ejection fraction. SELECT (Lincoff et al. 2023, NEJM) is the trial that drove the cardiovascular label expansion. FLOW (Perkovic et al. 2024, NEJM) shows a 24 percent reduction in kidney disease progression and CV death, useful if you have CKD.<\/p>\n

Pick the two trials that match your situation. Don’t cite all of them. Aetna’s reviewers know the literature, and a focused letter looks more credible than a literature review.<\/p>\n

Key Takeaway: The SELECT trial cardiovascular indication (FDA approved March 2024) creates a separate medical-necessity pathway distinct from obesity coverage<\/p>\n

What If Aetna Upholds the First Denial?<\/h2>\n

If your level-1 appeal is denied, you have two options that run in parallel: a level-2 internal appeal with Aetna, and an external review through your state insurance commissioner.<\/strong><\/p>\n

The level-2 internal appeal goes to a different reviewer than the level-1, usually a board-certified physician. You have 60 days from the level-1 denial to file. The packet can include the same documents plus a peer-to-peer review request, where your prescriber speaks directly with Aetna’s medical director.<\/p>\n

External review through your state commissioner is independent of Aetna and decisions are binding. The deadline varies by state but is usually 4 months from the final internal denial. The IRO (independent review organization) will assign a board-certified physician in the relevant specialty (endocrinology or obesity medicine for Wegovy) and the review costs you nothing. Approval rates at external review average around 50 percent for prescription drug denials.<\/p>\n

Does the SELECT Trial Change Anything for Cardiovascular Patients?<\/h2>\n

Yes, and it’s the strongest pivot point in a 2026 Wegovy appeal.<\/strong> In March 2024, the FDA approved Wegovy for cardiovascular risk reduction in adults with established CVD and either obesity or overweight. That is a separate label from the obesity indication.<\/p>\n

If you have a history of MI, ischemic stroke, or symptomatic peripheral arterial disease, your appeal should lead with the CVD indication, not the obesity indication. The 6-month lifestyle program requirement is waived under most Aetna plans for the CV indication. Cite SELECT (Lincoff et al. 2023, NEJM) and note that the trial enrolled 17,604 patients and showed a hazard ratio of 0.80 for the primary MACE endpoint.<\/p>\n

Your prescriber’s LMN should explicitly say “requested for cardiovascular risk reduction per FDA-approved indication, not for weight loss alone.” That single sentence reroutes the review.<\/p>\n

What If My Employer Carved Out Weight-loss Drugs?<\/h2>\n

This is the hardest denial to overturn, and it cannot be appealed through Aetna.<\/strong> The benefit design comes from the employer’s plan document, not Aetna’s medical policy.<\/p>\n

You have three options. First, ask HR whether the carve-out applies to all indications or only the obesity indication. If the cardiovascular indication is covered separately, you may qualify. Second, request a formulary exception based on medical necessity. Some self-funded employer plans allow exceptions for documented CVD or type 2 diabetes with proven prior intolerance to alternatives. Third, look at affordable cash-pay options. Compounded semaglutide through a licensed telehealth provider like TrimRx can run a fraction of the brand-name price, and a free assessment quiz determines eligibility in a few minutes.<\/p>\n

Brand-name Wegovy through Novo Nordisk’s NovoCare program has a savings card that can drop the cost to about $650 per month for patients without coverage, but the program has income and insurance-status restrictions.<\/p>\n

How Long Does the Full Appeal Process Take?<\/h2>\n

A standard level-1 internal appeal takes 30 days.<\/strong> A level-2 takes another 30 days. External review is usually 45 days but can be expedited to 72 hours if your prescriber documents urgent medical need.<\/p>\n

Total timeline if you exhaust every path: roughly 4 to 5 months from the initial denial to a final external review decision. Expedited appeals can collapse this to 10 to 14 days end to end.<\/p>\n

While appeals are pending, you have a few interim options: pay cash and seek reimbursement if the appeal succeeds, use the Wegovy savings card if eligible, or start a personalized treatment plan with a compounded GLP-1 through a telehealth provider while the appeal is in review.<\/p>\n

Bottom line: External review through your state insurance commissioner is free and decisions are binding on Aetna<\/p>\n

FAQ<\/h2>\n

Can I Appeal an Aetna Wegovy Denial Without My Doctor’s Help?<\/h3>\n

Technically yes, but the approval rate drops sharply without a Letter of Medical Necessity from the prescriber. The LMN carries clinical authority that a patient-written letter cannot. Most prescribers will write one if you ask the office in writing and provide the denial letter.<\/p>\n

Does Aetna Cover Wegovy for Medicare Patients?<\/h3>\n

Aetna Medicare Part D plans cover Wegovy only for the cardiovascular indication (CVD plus overweight or obesity), following the CMS coverage update in March 2024. Wegovy is not covered for weight loss alone under Medicare. The PA criteria require documented CVD with ICD-10 codes.<\/p>\n

How Much Does Brand-name Wegovy Cost Without Insurance?<\/h3>\n

The list price is approximately $1,349 per month in 2026. With the Novo Nordisk NovoCare savings card, eligible commercially-insured patients can pay as little as $0 per month, and cash-pay patients can get the price down to about $499 through the NovoCare Pharmacy direct program launched in early 2024.<\/p>\n

Can I Switch to Compounded Semaglutide If the Appeal Fails?<\/h3>\n

Yes, and many patients do. Compounded semaglutide from a licensed 503A pharmacy is the same active ingredient as Wegovy, prescribed through a telehealth platform like TrimRx after a clinical assessment. The cost is typically $199 to $399 per month depending on dose. Compounded options remain legal when prescribed for an individual patient based on clinical need.<\/p>\n

What If Aetna Requires STEP Therapy with Contrave or Phentermine?<\/h3>\n

Step therapy can be overridden with a medical exception if your prescriber documents intolerance, contraindication, or prior failure of the step drugs. Contrave is contraindicated with seizure disorders, uncontrolled hypertension, and chronic opioid use. Phentermine is contraindicated with cardiovascular disease and uncontrolled hypertension. Document any of these and the step requirement is waived.<\/p>\n

How Long Do I Have to File an External Review?<\/h3>\n

Most states allow 4 months from the final internal denial to file external review. A few states give 120 days exactly. Check your state insurance commissioner’s website for the precise deadline. Filing instructions are typically a one-page form plus copies of the prior denial letters.<\/p>\n

Will Aetna Pay Back What I Spent During the Appeal?<\/h3>\n

If your appeal succeeds, Aetna is required to reimburse covered amounts retroactive to the date the prior authorization should have been approved. Keep every receipt, pharmacy invoice, and prescription record from the period the appeal was pending. Reimbursement is processed within 30 to 45 days of the approval decision.<\/p>\n

Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n

<\/p>\n

Related Articles<\/h2>\n